NCT00264134终止1 期
A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma
Kentuckiana Cancer Institute2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2003年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
研究概览
简要总结
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
详细描述
A phase I/II dose escalating study to determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older unresectable lung cancer measurable or evaluable lesions Karnofsky PS greater than or equal to 60%
排除标准
- •untreated CNS metastases
结局指标
主要结局
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
次要结局
- Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric CancerEsophageal CancerStomach CancerNCT00394433Dana-Farber Cancer Institute38
已完成
1 期
Chemotherapy for Patients With Cancer of the StomachFirst-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus orNCT01928524Per Pfeiffer34
终止
1 期
Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate CancerProstate CancerProstatic NeoplasmsNCT00861471NYU Langone Health24
Unknown
2 期
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.SarcomaNCT01380275National Cancer Center, Korea35
已完成
1 期
Docetaxel and Sirolimus in Patients With Advanced MalignanciesAdvanced CancerNCT01054313M.D. Anderson Cancer Center103